A PHASE 3, MULTI-REGIONAL, OPEN-LABEL, RANDOMIZED STUDY OF TIRABRUTINIB VS RITUXIMAB AND TEMOZOLOMIDE IN PARTICIPANTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Registry ID

ONO-4059-17

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ONO PHARMACEUTICAL CO LTD

Last update

2026-05-06

Conditions

• CENTRAL NERVOUS SYSTEM LYMPHOMA

Related clinical trials

• A PHASE 2 STUDY OF IBRUTINIB COMBINATION THERAPY IN TRANSPLANT INELIGIBLE INDIVIDUALS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

View on source registry